# US 2026/0234647 A1 · Expression of modified proteins in a peroxisome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234647 A1
- Document ID: US20260234647A1
- Status: Published application
- Kind: A1
- Application number: 19/260,158
- Filed: 2025-07-03
- Published: 2026-08-13
- Earliest claimed: 2019-05-14
- Assignees: The Regents of the University of California
- Applicants: Provenance Bio, LLC
- Inventors: Genevieve M. Vidanes; John Dueber; Zev Gartner; Chirag Vazirani
- Web page: https://patentgrep.com/patent/US20260234647A1

## CPC

- C12N 15/81: for yeasts
- C07K 14/4732: {Casein (in foodstuffs A23J)}
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C07K 14/77: Ovalbumin
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 9/506: {derived from RNA viruses}
- C12N 9/90: Isomerases (5.)
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/62: DNA sequences coding for fusion proteins
- C12Y 114/11002: Procollagen-proline dioxygenase (1.14.11.2), i.e. proline-hydroxylase
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- C12Y 304/22044: Nuclear-inclusion-a endopeptidase (3.4.22.44)
- C12Y 503/04001: Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
- C07K 2319/50: containing protease site
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein include methods and compositions for making proteins in peroxisomes as well as methods of making cells for producing proteins in peroxisomes. Also disclosed herein are cells for producing a protein in a peroxisome, and methods for producing a protein in a eukaryotic cell containing a peroxisome as described herein.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of producing a modified protein in a peroxisome of a eukaryotic cell, the method comprising:
culturing a eukaryotic cell comprising a peroxisome;
expressing in the eukaryotic cell a heterologous protein comprising a peroxisome-targeting sequence, whereby the heterologous protein is localized to the peroxisome;
expressing in the eukaryotic cell a heterologous modification enzyme comprising a peroxisome-targeting sequence, whereby the heterologous modification enzyme is localized to the peroxisome; and
modifying the heterologous protein in the peroxisome with the heterologous modification enzyme, thereby producing the modified protein that comprises a modification.

### Claim 3 (depends on 2)

The method of claim 2, wherein the eukaryotic cell is a yeast cell.

### Claim 4 (depends on 3)

The method of claim 3, wherein the yeast cell is a genus of Arxula, Candida, Hansenula, Kluyveromyces, Komagataella, Ogataea, Pichia, Saccharomyces, or Yarrowia.

### Claim 5 (depends on 2)

The method of claim 2, wherein the peroxisome-targeting sequence comprises a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

### Claim 6 (depends on 2)

The method of claim 2, wherein the peroxisome-targeting sequence comprises an enhanced PTS1 sequence comprising LGRGRRSKL.

### Claim 7 (depends on 2)

The method of claim 2, wherein the heterologous modification enzyme is a prolyl hydroxylase, prolyl-4-hydroxylase, lysyl oxidase, prolyl isomerase, protein disulfide isomerase, chaperone protein, hydroxyl transferase, oxidase, protease, kinase, phosphatase, or glycosyltransferase.

### Claim 8 (depends on 2)

The method of claim 2, wherein the modification comprises hydroxylation, oxidation, proteolysis, phosphorylation, dephosphorylation, isomerization, disulfide bond formation or rearrangement, folding, assembly, or glycosylation.

### Claim 9 (depends on 2)

The method of claim 2, further comprising expressing in the eukaryotic cell a second heterologous modification enzyme comprising a peroxisome-targeting sequence, whereby the second heterologous modification enzyme is localized to the peroxisome.

### Claim 10 (depends on 2)

The method of claim 2, wherein the heterologous protein is collagen, gelatin, silk protein, a collagen fragment, a collagen peptide, a collagen-like peptide, or a synthetic collagen-like protein.

### Claim 11 (depends on 2)

The method of claim 2, wherein the heterologous protein comprises collagen or a collagen-like protein, wherein the heterologous modification enzyme comprises a prolyl hydroxylase, and wherein the modification comprises hydroxylation of one or more proline residues in the collagen or collagen-like protein.

### Claim 12 (depends on 11)

The method of claim 11, wherein the prolyl hydroxylase comprises prolyl-4-hydroxylase.

### Claim 13 (depends on 11)

The method of claim 11, wherein the collagen or collagen-like protein comprises COL1A1, COL1A2, COLsyn2, COLsyn3, or an amino acid sequence at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to COLsyn2 or COLsyn3, wherein COLsyn2 and COLsyn3 comprise the amino acid sequences set forth in SEQ ID NO: 26 and SEQ ID NO: 28, respectively.

### Claim 14 (depends on 11)

The method of claim 11, wherein the modified protein comprises a Type I collagen heterotrimer, a Type I collagen alpha homotrimer, a Type III collagen homotrimer, or a collagen chain modified by hydroxylation at one or more Y-position proline residues.

### Claim 15 (depends on 2)

The method of claim 2, wherein localization of the heterologous protein and the heterologous modification enzyme to the peroxisome increases yield of the modified protein relative to a corresponding cell in which the heterologous protein or the heterologous modification enzyme is not localized to the peroxisome.

### Claim 16 (depends on 15)

The method of claim 15, further comprising increasing cargo capacity of the peroxisome.

### Claim 17 (depends on 16)

The method of claim 16, wherein increasing cargo capacity of the peroxisome comprises providing oleic acid or methanol to the eukaryotic cell.

### Claim 18

An engineered eukaryotic cell comprising a peroxisome and comprising:
a first nucleic acid encoding a heterologous protein comprising a peroxisome-targeting sequence; and
a second nucleic acid encoding a heterologous modification enzyme comprising a peroxisome-targeting sequence;
wherein the engineered eukaryotic cell is configured to express the heterologous protein and the heterologous modification enzyme such that the heterologous protein and the heterologous modification enzyme are localized to the peroxisome and the heterologous modification enzyme modifies the heterologous protein in the peroxisome.

### Claim 19 (depends on 18)

The engineered eukaryotic cell of claim 18, wherein the engineered eukaryotic cell is a yeast cell of a genus of Arxula, Candida, Hansenula, Kluyveromyces, Komagataella, Ogataea, Pichia, Saccharomyces, and Yarrowia.

### Claim 20 (depends on 18)

The engineered eukaryotic cell of claim 18, wherein:
the heterologous protein comprises collagen, gelatin, silk protein, COL1A1, COL1A2, COLsyn2, COLsyn3, or an amino acid sequence at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to COLsyn2 or COLsyn3; and/or
the heterologous modification enzyme comprises a prolyl hydroxylase, prolyl-4-hydroxylase, protein disulfide isomerase, prolyl isomerase, lysyl oxidase, protein chaperone, hydroxyl transferase, oxidase, protease, kinase, phosphatase, or glycosyltransferase.

### Claim 21

A modified protein comprising:
a collagen or collagen-like protein modified by hydroxylation at one or more proline residues;
wherein the modified protein is produced by:
culturing a eukaryotic cell comprising a peroxisome;
expressing in the eukaryotic cell a heterologous protein comprising a peroxisome-targeting sequence, whereby the heterologous protein is localized to the peroxisome;
expressing in the eukaryotic cell a heterologous modification enzyme comprising a peroxisome-targeting sequence, whereby the heterologous modification enzyme is localized to the peroxisome; and
modifying the heterologous protein in the peroxisome with the heterologous modification enzyme, thereby producing the modified protein.
